In a recent update, analyst Rudy Li from Chardan Capital has maintained the "Buy" rating on Prothena Corp (PRTA, Financial) while significantly lowering the price target. The latest target price has been adjusted from USD 40.00 to USD 18.00, reflecting a 55% decrease.
The decision to lower the price target comes amid ongoing evaluations of Prothena Corp's strategic positioning and potential market developments. Despite the substantial reduction in the target price, the maintained "Buy" rating indicates a continued positive outlook on the company's long-term performance. Investors are encouraged to consider the revised target when making investment decisions related to Prothena Corp (PRTA, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Prothena Corp PLC (PRTA, Financial) is $36.00 with a high estimate of $81.00 and a low estimate of $6.00. The average target implies an upside of 447.11% from the current price of $6.58. More detailed estimate data can be found on the Prothena Corp PLC (PRTA) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Prothena Corp PLC's (PRTA, Financial) average brokerage recommendation is currently 2.4, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Prothena Corp PLC (PRTA, Financial) in one year is $28.79, suggesting a upside of 337.54% from the current price of $6.58. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Prothena Corp PLC (PRTA) Summary page.
